Filing Flows

Filing Flows › 8-K events › Ionis Pharmaceuticals

Ionis Pharmaceuticals: regulation fd disclosure

Form 8-K filed Oct 21, 2026 · items 7.01, 8.01

FDA decisionsIonis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

What the filing says

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB) – Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care –

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Ionis Pharmaceuticals at a glance

Latest quarterQ2 2026
Revenue$267.9M
Revenue Y/Y-41%
Operating margin-38.2%
IndustryPharmaceutical Preparations

Ionis Pharmaceuticals, Q2 2026: revenue $268M (-41% year over year), operating margin -38.2%. The chart follows the revenue to costs, profit and cash.

Ionis Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.